Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SANA vs KALV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KALV Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)

KALV Overall Winner 6-Pillar Tally: SANA 2 – 3 KALV (1 Tie) Matrix Metrics: SANA 3 – 7 KALV

As of Nov 16, 2026, KalVista Pharmaceuticals, Inc. (KALV) is the stronger overall head-to-head candidate over Sana Biotechnology, Inc. (SANA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). SANA carries a Unified Composite Score of 44.3/100 (HOLD) at $1.88 (N/M Forward P/E, 0.0% operating margin), whereas KALV carries 55.1/100 (HOLD) at $27.00 (25.4x Forward P/E, -57.4% operating margin).

  • Technical & Structure Timing Caution: SANA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6); meanwhile KALV trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 76.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SANA vs KALV
SANA NASDAQ
Sana Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.88
-6.93% 1D
Market Cap $605.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.82β · 78% Vol
Unified Composite Score
44.3 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 66.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.0%), weak momentum, RSI 31
RSI-14: 30.6 · SMA20: $2.37 · SMA50: $2.68
KALV NASDAQ Head-to-Head Winner
KalVista Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$27.00
+0.04% 1D
Market Cap $1.4B
TTM Revenue $114M
Forward P/E 25.4x
Beta / 30D Vol 0.85β · 2% Vol
Unified Composite Score
55.1 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 57.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (19.4% over 20 days), RSI 76
RSI-14: 76.0 · SMA20: $26.86 · SMA50: $24.01

6-Pillar Scorecard Institutional Category Breakdown (SANA 2 – 3 KALV)

Columns: Metric · SANA · KALV
1. Valuation Multiples KALV
Forward P/E N/M 25.4x
Trailing P/E N/M 25.4x
PEG Ratio N/M N/M
EV / Revenue N/M 12.6x
2. Growth & Scale KALV
Revenue Growth (YoY) +0.0% +30.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $114M
Market Cap $605.3M $1.4B
3. Profitability & Quality SANA
Gross Margin N/A 51.1%
Operating Margin 0.0% -57.4%
Net Profit Margin 0.0% -118.7%
Return on Equity (ROE) -79.5% -190.2%
4. Balance Sheet & Cash Flow KALV
Cash Generation (TTM) -$145M -$138M EBITDA
Cash Flow Margin N/A -120.9% EBITDA Mgn
Net Cash / Leverage $13M Net Debt (0.30x D/E) -190.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SANA
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 105.5% (4th %ile) 88.9% (31st %ile)
Put/Call OI Skew 0.61x (Call-Skewed) 26.28x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SANA (3) vs KALV (7)
Institutional Metric SANA KALV Criterion Row Edge
Market Capitalization
Scale
$605.3M $1.4B Larger Scale KALV
Trailing P/E Ratio
Valuation
N/M 25.4x Lower Multiple KALV
Forward P/E Ratio
Valuation
N/M 25.4x Lower Multiple KALV
Revenue Growth (YoY)
Growth
+0.0% +30.7% Higher Growth KALV
Operating Margin (TTM)
Profitability
0.0% -57.4% Higher Margin SANA
Net Profit Margin
Profitability
0.0% -118.7% Higher Margin SANA
Return on Equity (ROE)
Capital Efficiency
-79.5% -190.2% Higher ROE SANA
52-Week Range Position
Momentum
1% ($2–$5) 100% ($10–$27) Stronger Trend KALV
Beta / 30D Volatility
Risk Regime
1.82β · 78% Vol 0.85β · 2% Vol Lower Realized Risk KALV
Unified Institutional Score
Composite Signal
44.3 / 100 (HOLD) 55.1 / 100 (HOLD) Higher Composite KALV
Trailing 12M Revenue (USD)
Operating Scale
N/A $114M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 51.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 12.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$145M ($13M Net Debt (0.30x D/E)) -$138M EBITDA (-190.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KALV +21.88 pp
SANA: -20.79% · KALV: +1.09%
3M Horizon KALV +58.51 pp
SANA: -10.48% · KALV: +48.03%
6M Horizon KALV +99.23 pp
SANA: -39.09% · KALV: +60.14%
1Y Horizon KALV +129.21 pp
SANA: -22.95% · KALV: +106.26%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SANA vs KALV. Trailing 12-month operating profitability (SANA 0.0% vs KALV -57.4%) and valuation multiples (SANA N/M vs KALV 25.4x Forward P/E) are benchmarked directly in Pillar 4 below.

SANA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-79.5% · N/M
KALV ADR TTM Benchmark FX-Normalized USD
TTM Revenue$114M
Gross Margin51.1%
Op. Margin-57.4%
ROE / Fwd P/E-190.2% · 25.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SANA BREAKDOWN
57d in phase · OBV NEUTRAL
Current IV 105.5%
IV Percentile 4th %ile
Put/Call OI Skew 0.61x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SANA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KALV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 88.9%
IV Percentile 31st %ile
Put/Call OI Skew 26.28x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact KALV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SANA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $605.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
KALV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4B market capitalization and -57.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SANA vs KALV Key Questions & Quantitative Answers

As of Nov 16, 2026, KalVista Pharmaceuticals, Inc. (KALV) is the stronger overall head-to-head candidate over Sana Biotechnology, Inc. (SANA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). SANA carries a Unified Composite Score of 44.3/100 (HOLD) at $1.88 (N/M Forward P/E, 0.0% operating margin), whereas KALV carries 55.1/100 (HOLD) at $27.00 (25.4x Forward P/E, -57.4% operating margin). Technical & Structure Timing Caution: SANA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6); meanwhile KALV trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 76.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KALV leads the Growth & Scale pillar: SANA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with KALV at +30.7% YoY revenue growth and +0.0% YoY earnings growth on $114M TTM revenue (51.1% gross margin, -57.4% operating margin). On trailing 12-month operating scale, SANA generates N/A in USD-normalized revenue versus $114M for KALV. In operating R&D and SG&A reinvestment, SANA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KALV.

KALV screens cheaper on headline valuation multiples. SANA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas KALV trades at 25.4x Forward P/E, 25.4x Trailing P/E, N/M PEG, and 12.6x EV/Revenue (-120.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SANA (-79.5% ROE) versus KALV (-190.2% ROE) capital efficiency.

In options market volatility and institutional positioning, SANA carries 105.5% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.61x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 78% Vol realized risk). By comparison, KALV carries 88.9% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 26.28x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.85β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.